A Phase 1 interventional study of 0.5% VVN432 Nasal Spray and 1% VVN432 Nasal Spray in Chronic Rhinosinusitis (CRS), sponsored by VivaVision Biotech, Inc. Recruiting at 1 site in China. Open to participants aged 18 Years to 55 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2025-12-02.
Sponsored by VivaVision Biotech, Inc · Phase 1, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 40 studies in Rhinosinusitis with a site in China — 18 open to participants now, 25 under way, 7 of them phase 3. Rhinosinusitis · China.
Among the 40 studies in Rhinosinusitis with a site in China, this one is the 30th largest by planned enrollment of the 36 interventional ones that give a count, is one of 10 that started in 2025, is the only one in phase 1, reaches primary completion later than 7 of the 24 other live ones, and was the 30th registered.
252 studies on the registry are indexed under Rhinosinusitis; 70 are open to participants now.
Browse Rhinosinusitis studies →18 of the 40 studies in Rhinosinusitis with a site in China are open now. Recruiting first, the newest first:
AstraZeneca · Sites in China
Ages 18+
Bambusa Therapeutics · Sites in China
Ages 18–75 · Healthy volunteers
Tang-Du Hospital · Sites in China
Ages 18–65
Guangdong Hengrui Pharmaceutical Co., Ltd · Sites in China
Ages 18–75
The Affiliated Hospital of Qingdao University · Sites in China
Ages 18–65
A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →
Of the 34 Rhinosinusitis studies recruiting now, 15 (44%) set no upper age limit and 13 (38%) stop at 75 or younger; 4 take children under 18; 7 take healthy volunteers.
This study: 18 Years to 55 Years · all sexes · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
40 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 5 · Phase 2 16 · Phase 3 11 · Phase 4 3
First in 2014; this study’s year is marked. 10 started in 2025.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 60 is below the median of 74 across 177 interventional studies indexed under Rhinosinusitis.
Median enrollment 117 across the 36 interventional studies, 75 across the 4 observational. Of the 12 that completed or were terminated, 3 (25%) have results posted.
This tab as a report to print or save as PDF → With an account.
26 of 40 have an industry lead sponsor. The 10 most frequent:
VivaVision Biotech, Inc is the lead sponsor of 8 studies on the registry; 2 are open to participants now.
VivaVision Biotech, Inc has 1 study filed under Rhinosinusitis — fewer than ten, so there is no comparison to draw.
9 of the studies in Rhinosinusitis with a site in China that are under way reach primary completion within a year, 4 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07424144Phase 3SanofiAn Extension Study to Investigate the Long-term Safety and Tolerability of Itepekimab in Adult Participants With Inadequately Controlled Chronic Rhinosinusitis With Nasal Polyps | 2027-02-17 |
| NCT07107256Phase 3Shanghai Chia Tai Tianqing Pharmaceutical Technology Development Co., Ltd.Clinical Trial of TQC2731 Injection in Patients With Chronic Sinusitis and Nasal Polyps | 2027-03 |
| NCT06338995Phase 3Eli Lilly and CompanyA Study of Lebrikizumab (LY3650150) in Participants With Chronic Rhinosinusitis and Nasal Polyps Treated With Intranasal Corticosteroids (CONTRAST-NP) | 2027-05 |
| NCT07807826Phase 3Beijing Keymed Biosciences Co., Ltd.A Study of CM512 in Patients With Chronic Rhinosinusitis With Nasal Polyposis (NEZHA-3) | 2027-11 |
| NCT07313917Longbio PharmaA Study to Evaluate the Efficacy and Safety of LP-003 Injection in Patients With Chronic Rhinosinusitis With Nasal Polyps (CRSwNP) | 2027-02-28 |
Add all 9 to your calendar (.ics) → With an account.
Among the 40 studies in Rhinosinusitis with a site in China, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The goal of this clinical study is to evaluate the safety, tolerability, and pharmacokinetics (PK) of VVN432 Nasal Spray in healthy volunteers (Phase Ia) and in patients with chronic rhinosinusitis (Phase 1b).
This study consists of two parts (Phase 1a and Phase 1b):
Phase 1a (SAD) is a single-center, randomized, double-masked, vehicle-controlled study to assess the safety, tolerability, and PK of VVN432 Nasal Spray in healthy adult subjects.
Phase 1b (MAD) is a multi-center, randomized, double-masked, vehicle-controlled study to assess the safety, tolerability, PK/PD, and preliminary efficacy of VVN432 Nasal Spray in patients with chronic rhinosinusitis.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Part 1:
Part 2:
Exclusion Criteria:
Part 1:
Part 2:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
0.5% VVN432 Nasal Spray, single dose, 1 spray/nostril
Drug: 0.5% VVN432 Nasal Spray
1% VVN432 Nasal Spray, single dose, 1 spray/nostril
Drug: 1% VVN432 Nasal Spray
1% VVN432 Nasal Spray, single dose, 2 sprays/nostril
Drug: 1% VVN432 Nasal Spray
VVN432 Nasal Spray Placebo, single dose, 1 or 2 sprays/nostril
Drug: Vehicle
0.5% VVN432 Nasal Spray, BID, 1 spray/nostril, for 28 days
Drug: 0.5% VVN432 Nasal Spray
1% VVN432 Nasal Spray, BID, 1 spray/nostril, for 28 days
Drug: 1% VVN432 Nasal Spray
1% VVN432 Nasal Spray, BID, 2 sprays/nostril, for 28 days
Drug: 1% VVN432 Nasal Spray
VVN432 Nasal Spray Placebo, BID, 1 or 2 sprays/nostril, for 28 days
Drug: Vehicle
0.5% VVN432 Nasal Spray
1% VVN432 Nasal Spray
VVN432 Nasal Spray, Placebo
Part 1: To evaluate the safety and tolerability of VVN432 Nasal Spray.
Incidence of the AEs and SAEs; change from baseline in laboratory tests, ECG, and vital signs
Time frame: Baseline to Day 10
Part 2: To evaluate the safety and tolerability of VVN432 Nasal Spray
Incidence of the AEs and SAEs; change from baseline in laboratory tests, ECT, and vital signs
Time frame: Baseline to Day 35
Part 1: To evaluate the systemic PK of VVN432 Nasal Spray
Plasma concentration of VVN432, and assess the PK parameters if applicable
Time frame: 48 hours
Part 1: To evaluate the local PK of VVN432 Nasal Spray
Local concentration of VVN432 in the eluent of oropharyngeal swabs and nasal swabs, and in nasal lavage fluid post-dose
Time frame: 48 hours
Part 2: To evaluate the systemic PK of VVN432 Nasal Spray
Plasma concentration of VVN432, and assess the PK parameters if applicable
Time frame: Day 1, Day 28, and Day 35
Part 2: To evaluate the local PK of VVN432 Nasal Spray
Local concentration of VVN432 in the eluent of nasal swabs post-dose
Time frame: Day 1, Day 28, and Day 35
Part 2: Efficacy: Nasal Congestion Score (NCS)
Change from baseline in NCS (0-3, higher scores indicate more severe symptoms)
Time frame: Baseline to Day 35
Part 2: Efficacy: Total Symptom Score (TSS)
Change from Baseline in TSS (0-9 \[sum of NCS, loss of smell, and average of anterior and posterior rhinorrhea\], higher scores indicate more severe symptoms)
Time frame: Baseline to Day 35
Started Nov 2025 (actual). Primary completion is estimated for Jul 2026, 8 months after the start.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
VivaVision Biotech, Inc